// App-Quantinova.ai

4867 : The CD40 agonistic antibody APX005M licenses antigen presenting cells to promote tumor-specific T-cell responses

Researchers

Presenter

  • Erin L. Filbert

Principal Investigators

  • Pia Bjorck

  • Xiaodong Yang

  • Ovidiu C. Trifan

Medical Centers

  • Apexigen, San Carlos, CA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • Cluster of differentiation 86

  • Human Leukocyte Antigen – DR isotype

  • Interleukin 12

Drug/Treatment

  • OX40L

  • IL-12

  • IFN-lambda

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved